DeJin Medical Recognized as a 'Gazelle Enterprise' for Pioneering Innovation in Structural Heart Therapies

Recently, the first batch of "Gazelle Enterprises" list for 2024 in Hangzhou High-tech Industrial Development Zone was officially announced. Valgen Medtech stood out in the strict selection process with its continuous innovation and rapid growth in the field of interventional treatment for structural heart disease, successfully making it onto the list. This marks Valgen Medtech'sR&D Capabilities, Innovative TechnologiesAndDevelopment PotentialHas gained high authoritative recognition from both the government and the market.

"Gazelle Enterprises" usually refer to those high-tech enterprises that are as nimble and agile as gazelles, have good growth potential, and exhibit a leaping development trend. They are driven by technological innovation as their core, achieving rapid breakthroughs in niche fields, becoming the "barometer" of regional economic vitality.

In the growth梯队 of innovative enterprises, "瞪羚 enterprises" are regarded as a crucial stage for nurturing future "unicorn" enterprises, serving as a clear indicator of high potential and rapid growth.Valgen Medtech, which has been named a "unicorn" multiple times, is already an industry leader.

Since its establishment in 2015, Valgen Medtech hasDeeply engaged in structural heart disease, particularly in the field of atrioventricular valve interventional treatmentOver the past decade, the company's R&D team has adhered to a spirit of perseverance and bold innovation, successfully completing its core product—DragonFly™ Transcatheter Mitral Valve Clip SystemCountless iterations and rigorous clinical validations. This long-term commitment to innovation is the very foundation of today's "Gazelle" recognition.

The traits of a gazelle company are vividly embodied in Valgen Medtech's globalization process. The company's innovative products have not only gained a solid foothold in the Chinese market but also rapidly expanded into international markets with astonishing speed.

• November 2023: DragonFly™ successfully obtained marketing approval from the National Medical Products Administration (NMPA) of China, marking a new chapter in serving patients in China.

• 2024 to 2025: The product, with unprecedented "China speed," efficiently entered many core strategic markets worldwide, including Europe, Asia, Latin America, and the Middle East, successfully obtaining a series of key access certifications.

Especially in April 2025, DragonFly™ successfully passed the stringent EU MDR certification, becoming the first product in China's same field to obtain this certification. The rapid acquisition of this series of international certifications is a strong testament to Valgen Medtech's technological innovation capabilities meeting the highest global standards, and also demonstrates its swift momentum as a "gazelle enterprise" to seize the commanding heights of the global market.

From "National High-tech Enterprise" and "Zhejiang Province Specialized, Fine, New Small and Medium-sized Enterprise" to today's "Gazelle Enterprise," Valgen Medtech has clearly outlined the growth path of a high-growth company through a series of authoritative certifications.

It is by no means an endpoint, but rather a sign that the company's innovative value and development potential are being continuously validated and amplified. This not only affirms past achievements but also indicates that its innovative value and development potential are entering a new phase of continuous validation and amplification. We firmly believe that this is just the beginning. Valgen Medtech is bound to deliver frequent good news on the global stage, bringing a more profound "China impact" to the industry landscape.

————  Previous Review ————